Trials / Withdrawn
WithdrawnNCT03671720
Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Capital Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is to investigate the safety and efficacy of dendritic cells vaccines pulsed with autologous whole tumor cell lysate for treating advanced solid tumor patients with high tumor mutation burden.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | personalized DC vaccine | personalized vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous tumor cells, administered intranodally on day 1,8,15, with a combination of oral cyclophosphamide (50mg) every day except the day of vaccine administrations.Cycles are repeated every 21 days. Treatment is continued until disease progression or exhaustion of vaccine supply, whichever comes first. |
Timeline
- Start date
- 2018-09-11
- Primary completion
- 2021-12-30
- Completion
- 2022-12-30
- First posted
- 2018-09-14
- Last updated
- 2024-02-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03671720. Inclusion in this directory is not an endorsement.